Juno Therapeutics was founded in 2013 and is headquartered in Seattle, US
Key People at Juno Therapeutics
Hans Bishop
CEO
Juno Therapeutics Office Locations
Juno Therapeutics has offices in Seattle, Washington, Bothell, Waltham and in 2 other locations
Seattle, US (HQ)
300 307 Westlake Ave N
Juno Therapeutics Data and Metrics
Juno Therapeutics Financial Metrics
Juno Therapeutics's revenue was reported to be $79.4 m in FY, 2016 which is a 336% increase from the previous period.
$, USD
Revenue (FY, 2016) | 79.4 m |
Revenue growth (FY, 2015 - FY, 2016), % | 336% |
Net income (FY, 2016) | (245.6 m) |
EBIT (FY, 2016) | (255.6 m) |
Market capitalization (23-Jun-2017) | 3 b |
Closing share price (23-Jun-2017) | 27 |
Cash (31-Dec-2016) | 187.9 m |
Juno Therapeutics's current market capitalization is $3 b.
- Source: SEC Filings
| $, USD | FY, 2015 | FY, 2016 |
|---|---|---|
Revenue | 18.2 m | 79.4 m |
Revenue growth, % | 336% | |
R&D expense | 46.2 m | 264.3 m |
General and administrative expense | 4.2 m | 70.7 m |
Operating expense total | 51.7 m | 335 m |
EBIT | (51.7 m) | (255.6 m) |
EBIT margin, % | (284%) | (322%) |
Pre tax profit | (51.8 m) | (256.2 m) |
Income tax expense | 2.8 m | 10.7 m |
Net Income | (51.8 m) | (245.6 m) |
- Source: SEC Filings
| $, USD | FY, 2015 | FY, 2016 |
|---|---|---|
Cash | 252.4 m | 187.9 m |
Accounts Receivable | 315 k | 13.3 m |
Inventories | 8.4 m | 26.5 m |
Current Assets | 951.8 m | 772.3 m |
PP&E | 42.1 m | 81.7 m |
Goodwill | 122.1 m | 221.3 m |
Total Assets | 1.4 b | 1.3 b |
Accounts Payable | 4.2 m | 4.4 m |
Current Liabilities | 119.7 m | 114.9 m |
Additional Paid-in Capital | 1.7 b | 1.9 b |
Retained Earnings | (585.7 m) | (831.2 m) |
Total Equity | 1.1 b | 1.1 b |
Financial Leverage | 1.3 x | 1.3 x |
| $, USD | FY, 2015 | FY, 2016 |
|---|---|---|
Net Income | (51.8 m) | (245.6 m) |
Depreciation and Amortization | 2 k | 14.2 m |
Accounts Receivable | 33 k | (13 m) |
Accounts Payable | (2.7 m) | 3.7 m |
Cash From Operating Activities | (103.6 m) | (189.8 m) |
Purchases of PP&E | (42 k) | (56.2 m) |
Cash From Investing Activities | (42 k) | 88.6 m |
Cash From Financing Activities | 66.5 m | 36.8 m |
| $, USD | Y, 2016 |
|---|---|
Revenue/Employee | 212.8 k |
Financial Leverage | 1.3 x |
Juno Therapeutics Operating Metrics
Juno Therapeutics's Patent Applications was reported to be 481 in FY, 2016
- Source: SEC Filings
